CTRI/2021/04/033036已完成未知
A Randomized, Open Label, Balanced, Two-Treatment, One-Sequence, One-Period, Multiple-Dose, Parallel Design, Steady-State Comparison Study of Test Product (T) [Remdesivir Sublingual Tablets 20 mg (Dose 200 mg/day) of Jubilant Generics Limited, India] with Reference Product (R) [Jubi-RTM (Remdesivir for injection 100 mg) (Loading Dose 200 mg/day, Maintenance Dose 100 mg/day) of Jubilant Generics Limited, India] in Healthy Adult, Human Subjects, Under Fasting Conditions. - REMD-21-012, Version 00
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects between 18 â?? 45 years of age (both inclusive).
- •2. Subjects who are able to read and write the vernacular language (English/Hindi) and understand the study requirements.
- •3. Must have provided written informed consent voluntarily for participation in the study in the subjectâ??s vernacular language (English/Hindi).
- •4. Weight between 50.00 â?? 80.00 Kg in case of Male (both inclusive) or 45.00 â?? 75.00 Kg in case of Female (both inclusive).
- •5. BMI 18.50 â?? 24.90 Kg/m2 (both inclusive).
- •6. Healthy as determined by medical history, clinical and laboratory examination performed within 21 days prior to admission for the study.
- •7. In the opinion of the Principal Investigator/Co-Investigator/Designee, be able to comply with the study procedures and protocol restrictions.
- •8. If female, and of childbearing potential (defined as a pre-menopausal female who is biologically capable of becoming pregnant), the subject must agree to practice a medically acceptable form of contraception from admission till close out visit of the clinical study. Acceptable forms of contraception include intrauterine devices, implant-able devices, and barrier methods. If a barrier method is chosen, a double barrier (e.g., condom plus foam) is required.
排除标准
- •1. Known hypersensitivity or idiosyncratic reaction to Remdesivir, its excipients or similar classes of drugs.
- •2. Any evidence of significant abnormalities upon physical or clinical examination.
- •3. Laboratory values, which are significantly different from pre-defined reference ranges and judged clinically significant.
- •4. Consumption of grapefruit juice/ grapefruit at least 48-hours prior to admission.
- •5. Any clinically significant abnormality in Chest X-Ray (PA view).
- •6. Any clinically significant abnormality in ECG.
- •7. Evidence of QT prolongation, QTc (Rate adjusted QT interval) > 450ms (in case of male) or 460ms (in case of female)
- •8. Serum alanine transaminase (ALT) levels above 2x upper limit of normal (ULN) or total bilirubin > 1.3x ULN or Serum creatinine levels above 1.5x upper limit of normal.
- •9. History of treatment with antiplatelet/anticoagulant/fibrinolytic agents.
- •10. Past or present use of tobacco and nicotine in any form.
- •11. History of drug dependence or excessive alcohol intake on a habitual basis, or, inability to abstain from alcohol for the entire duration of study period.
- •12. History or presence of significant gastrointestinal, hepatic, renal, cardiovascular, pulmonary, neurological, hematologic, or endocrine disease.
- •13. History of allergy to Heparin, dye and preservatives.
- •14. History or presence of any chronic illnesses such as arthritis, asthma, epilepsy, hypertension, glaucoma etc.
- •15. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses and syphilis.
- •16. Positive result for drug(s) of abuse testing (amphetamines, barbiturates, benzodiazepines, tetrahydrocannabinol, morphine, and cocaine) in urine.
- •17. Positive test for alcohol upon breath analyser testing.
- •18. History or presence of any allergic illness including allergic skin diseases, allergic asthma and drug-induced allergy, e.g., allergy due to amoxicillin, ampicillin, penicillin, tetracycline and Non-steroidal anti-inflammatory drugs (like ibuprofen and naproxen) etc.
- •19. History of intake/administration of any investigational treatment in a clinical study within last 90 days prior to the onset of the study admission.
- •20. History of significant blood loss (>= 350 mL) due to any reason, including blood donation within last 90 days prior to admission of the study.
- •21. History or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of the drug.
- •22. Existence of any surgical or medical condition which in the judgement of Principal Investigator/Designee might interfere with the absorption, distribution, metabolism or elimination of the study drug, or, is likely to compromise the safety of subject.
- •23. Intake of any enzyme-modifying drugs such as cimetidine, theophylline, benzodiazepines, ranitidine, repaglinide, midazolam, proton pump inhibitors, antacids, erythromycin, diuretics, ketoconazole, anti-hypertensive drugs, dopamine agonists, busulfan, bile acid sequestrants, aluminum containing antacids, agents metabolized by CYP3A4, CYP2C8 and CYP1A2, agents Inducing UDP-glucuronosyltransferase (UGT) Metabolism, Cholestyramine etc. within 30 da
研究者
相似试验
已完成
1 期
Comparative pharmacokinetic exposure evaluation of two formulations of Remdesivir in healthy adult human subjects.CTRI/2021/03/031661Jubilant Generics Limited24
尚未招募
不适用
Bioequivalence Study of [Follicle Stimulating Hormone (Human Recombinant)] Foligraf® 900 IU (66.0 mcg) / 1.5mL Solution for Injection in Healthy, Adult, Female, Human Subjects.CTRI/2022/04/041980Bharat Serums and Vaccines Limited
尚未招募
1 期
A Bioequivalence study of loratadine 5mg Chewable Tablets of AFT Pharmaceuticals compared with Children's Claratyne® Grape 5mg Chewable Tablets in healthy human adults under fasting conditions.ACTRN12624000019505AFT Pharmaceuticals Ltd32
尚未招募
2 期
A study to evaluate the blood levels of Brivaracetam SR Tablets 200 mg to measure the pharmacokinetic profiles, safety and tolerability of the Test product (of Optimus Pharma Pvt. Ltd.) when compared to the reference product (BRITZILAM SR Tablets 200 mg) in a healthy subject in a fasting condition.CTRI/2024/02/062873Optimus Pharma Pvt Ltd
已完成
1 期
Bioequivalence study of Clonazepam 0.5 mg mouth dissolving TabletCTRI/2017/08/009515Abbott Healthcare Private Limited30